ZA888981B - D-cycloserine and its prodrugs as cognitive enhancers - Google Patents

D-cycloserine and its prodrugs as cognitive enhancers

Info

Publication number
ZA888981B
ZA888981B ZA888981A ZA888981A ZA888981B ZA 888981 B ZA888981 B ZA 888981B ZA 888981 A ZA888981 A ZA 888981A ZA 888981 A ZA888981 A ZA 888981A ZA 888981 B ZA888981 B ZA 888981B
Authority
ZA
South Africa
Prior art keywords
cycloserine
prodrugs
cognitive enhancers
cognitive
enhancers
Prior art date
Application number
ZA888981A
Other languages
English (en)
Inventor
Alex A Cordi
A Cordi Alex
Gail E Handelmann
E Handelmann Gail
Joseph B Monahan
B Monahan Joseph
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of ZA888981B publication Critical patent/ZA888981B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA888981A 1987-12-01 1988-11-30 D-cycloserine and its prodrugs as cognitive enhancers ZA888981B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/127,121 US4904681A (en) 1987-12-01 1987-12-01 D-cycloserine and its prodrugs as cognitive enhancers

Publications (1)

Publication Number Publication Date
ZA888981B true ZA888981B (en) 1990-01-31

Family

ID=22428413

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA888981A ZA888981B (en) 1987-12-01 1988-11-30 D-cycloserine and its prodrugs as cognitive enhancers

Country Status (20)

Country Link
US (1) US4904681A (enExample)
EP (2) EP0319824B1 (enExample)
JP (2) JPH0621065B2 (enExample)
KR (1) KR0134198B1 (enExample)
AT (1) ATE68698T1 (enExample)
AU (4) AU622630B2 (enExample)
CA (1) CA1328617C (enExample)
DE (1) DE3865817D1 (enExample)
DK (1) DK173589B1 (enExample)
ES (1) ES2040314T3 (enExample)
FI (1) FI885559A0 (enExample)
GR (1) GR3003571T3 (enExample)
IE (1) IE61825B1 (enExample)
IL (1) IL88531A (enExample)
NO (1) NO885337D0 (enExample)
NZ (1) NZ227131A (enExample)
PH (1) PH26467A (enExample)
PT (1) PT89109B (enExample)
WO (1) WO1989005144A1 (enExample)
ZA (1) ZA888981B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5260324A (en) * 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5066665A (en) * 1990-05-21 1991-11-19 Warner-Lambert Co. Substituted isoxazolidin-3-ones and derivatives thereof acting at muscarinic receptors
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
NZ260302A (en) * 1994-04-13 1996-05-28 New Zealand Meat Ind Res Inst Treating bait aversion by including substances which disrupt the associative learning process into bait compositions
AU4128896A (en) * 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury
AU4019395A (en) * 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
ATE204852T1 (de) * 1995-02-15 2001-09-15 Bearsden Bio Inc Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
US6361957B1 (en) 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
FR2742748B1 (fr) * 1995-12-21 1998-01-30 Adir Nouveau derive de 4-imidazolidinone, son procede de preparation et les compositions pharmaceutiques qui le contiennent
KR100396114B1 (ko) * 1996-10-31 2003-11-20 동아제약 주식회사 D-시클로세린의 제조방법
AU765603C (en) * 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
EP1084704B1 (en) * 1998-06-10 2006-03-29 Meiji Seika Kaisha Ltd. Remedies for spinocerebellar ataxia and compositions for treating spinocerebellar ataxia
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20060252761A1 (en) * 2001-03-29 2006-11-09 Michael Davis Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
ATE519485T1 (de) * 2001-03-29 2011-08-15 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
CN1527813A (zh) 2001-04-02 2004-09-08 О 作为治疗剂的抗氧化剂硝基氧和亚硝氮碳基
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
UA80055C2 (en) * 2003-05-27 2007-08-10 Forest Laboratories Combination of nmda-receptor antagonist and selective inhibitor of serotonin reuptake for a depression and other pscihiatric disorders treatment
EP1660634A4 (en) * 2003-08-08 2009-02-18 Burnham Inst P16-mediated regulation of NMDA receptors
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
SG10201501050RA (en) 2010-02-11 2015-04-29 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
JP6419087B2 (ja) 2013-01-29 2018-11-07 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
CA2898861C (en) 2013-01-29 2021-07-20 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2014120784A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG11201505937SA (en) 2013-01-29 2015-09-29 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
CN105308049A (zh) 2013-01-29 2016-02-03 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP2019527235A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタム及びビス−スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
EP3490992B1 (en) 2016-08-01 2023-03-22 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109890825B (zh) 2016-08-01 2022-03-11 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3010599A1 (de) * 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung

Also Published As

Publication number Publication date
JPH0621065B2 (ja) 1994-03-23
DK669088D0 (da) 1988-11-30
IL88531A0 (en) 1989-06-30
IE883567L (en) 1989-06-01
PT89109B (pt) 1993-07-30
ES2040314T3 (es) 1995-04-01
EP0319824B1 (en) 1991-10-23
EP0421997A1 (en) 1991-04-17
WO1989005144A1 (en) 1989-06-15
AU2631988A (en) 1989-06-01
FI885559A0 (fi) 1988-11-30
JPH05201859A (ja) 1993-08-10
KR890009392A (ko) 1989-08-01
DE3865817D1 (enExample) 1991-11-28
IE61825B1 (en) 1994-11-30
ATE68698T1 (de) 1991-11-15
AU7746794A (en) 1995-01-05
KR0134198B1 (ko) 1998-04-21
DK669088A (da) 1989-06-02
PH26467A (en) 1992-07-27
NZ227131A (en) 1991-09-25
CA1328617C (en) 1994-04-19
AU1083992A (en) 1992-05-07
US4904681A (en) 1990-02-27
JPH01193220A (ja) 1989-08-03
AU622630B2 (en) 1992-04-16
PT89109A (pt) 1989-12-29
IL88531A (en) 1993-02-21
GR3003571T3 (enExample) 1993-03-16
NO885337D0 (no) 1988-11-30
AU2813089A (en) 1989-07-05
EP0319824A1 (en) 1989-06-14
DK173589B1 (da) 2001-04-02

Similar Documents

Publication Publication Date Title
AU2631988A (en) D-cycloserine and its prodrugs as cognitive enhancers
AU577369B2 (en) Cross-bar quadrupole source
DE3779053D1 (enExample)
GB8704032D0 (en) Light emitter bias stabilization
EP0562049A4 (en) Novel 4-arylpiperazines and 4-arylpiperidines
EP0435443A3 (en) Use of 15-keto-prostaglandin compound for improvement of encephalic function
NO174807C (enExample)
GR3004959T3 (enExample)
FI945626A0 (fi) Menetelmä 2,2-difluoriketeenisilyyliasetaalien ja alfa, alfa-difluori-beta-silyylioksi-1,3-dioksolaani-4-propaanihappoestereiden valmistamiseksi
DE3880982D1 (de) Bandspannungsvorrichtung.
PH25095A (en) Beta-alkylmelatonins
DE68902647D1 (en) Antiarthritische beta-cycloalkyl-beta-oxopropionitrile.
AU557394B2 (en) L-arginine isoxicamate
EP0405905A3 (en) Use of isoxazolin-3-one derivatives as antidepressants
DE3588208D1 (de) Cephalosporinderivative
AU538026B2 (en) Nitrile sulfenyl carbamates
FR2621212B1 (fr) Perfectionnement aux roues de plombage des semoirs
FR2611460B1 (fr) Perfectionneme nts aux etageres
AU554777B2 (en) Benzoquinolizines
FR2627937B2 (fr) Perfectionnement aux roues de plombage des semoirs
GR851608B (enExample)
BG41382A1 (en) Means for stabilizing synthetic elastomers